论文部分内容阅读
目的探讨卵巢癌患者血清中糖类抗原125(CA125)、癌胚抗原(CEA)、唾液酸(SA)联合检测的临床意义。方法抽取空腹静脉血2-3ml各两份,3000r/min下离心3min,采用全自动电化学发光免疫分析仪及试剂盒进行CA125、CEA检测,采用可见分光光度计及检测盒(比色法)进行SA检测。结果卵巢癌组血清CA125、SA的表达水平分别显著高于良性卵巢肿瘤组和健康对照组,经统计学分析,有显著性差异(P<0.05)。CA125、CEA、SA单独及联合检测的灵敏度、特异度不同,其中CA125、CEA、SA联合检测的灵敏度为最高,达到97.56%。结论 CA125、CEA、SA联合检测为卵巢癌的临床诊断、治疗提供了可靠的依据,值得临床广泛应用。
Objective To investigate the clinical significance of combined detection of serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and sialic acid (SA) in patients with ovarian cancer. Methods Fasting venous blood (2-3ml) was taken in duplicate and centrifuged at 3000r / min for 3 minutes. CA125 and CEA were detected by using an automatic chemiluminescence immunoassay analyzer and kit. The results of visible spectrophotometer and detection kit (colorimetric method) Perform SA test. Results The levels of serum CA125 and SA in ovarian cancer group were significantly higher than those in benign ovarian tumor group and healthy control group, respectively. There was a significant difference (P <0.05) by statistical analysis. The sensitivity and specificity of CA125, CEA and SA alone and in combination were different. The sensitivity of combined detection of CA125, CEA and SA was the highest (97.56%). Conclusion The combined detection of CA125, CEA and SA provides a reliable basis for the clinical diagnosis and treatment of ovarian cancer, which is worthy of clinical application.